文献速递多重用药老年慢病共病管理

老年人多重用药的纵向轨迹及其与死亡风险的关联:英国与荷兰真实世界数据的联合潜类别模型分析

Longitudinal trajectories of polypharmacy in older people, and their association with the risk of mortality: a joint latent class model analysis of real-world data from the UK and the Netherlands.
PubMed 文献 · Age Ageing · 2025-01-01

研究基于英国CPRD GOLD、CPRD Aurum和荷兰IPCI三个初级保健数据库,纳入2015年1月1日≥65岁人群,用联合潜类别模型识别多重用药轨迹聚类并关联死亡风险。在GOLD中训练模型,在Aurum和IPCI中验证,识别出四个聚类,其中 intermediate-fast/increasing 聚类进展最快且生存结局最差,高基线及增长的多重用药与死亡风险增加相关。

要点

  • 识别出四个多重用药轨迹聚类:低稳定、中等缓慢/增加、中等快速/增加、高下降。
  • 中等快速/增加聚类每年多重用药进展斜率最大(6.4),生存结局最差。
  • 高基线及增长的多重用药与老年人死亡风险增加相关。

核心结论

  • 高基线水平和增长的多重用药与老年人死亡风险增加相关。
  • 识别出的聚类在两个欧洲数据库中外部验证良好,具有稳健性和可推广性。

研究设计与样本

  • 基于英国CPRD GOLD、CPRD Aurum和荷兰IPCI三个初级保健数据库的真实世界数据。
  • 纳入2015年1月1日年龄≥65岁的人群。
  • 多重用药定义为处方成分累计数量,在基线和2015-19每年随访结束时计算。
  • 应用联合潜类别模型划分不同轨迹和死亡风险的聚类,在GOLD中训练,在Aurum和IPCI中验证。

主要发现

  • 识别出四个聚类:低稳定、中等缓慢/增加、中等快速/增加和高下降。
  • 高下降聚类平均基线多重用药最高(截距=23.4),非癌症慢性共病患病率最高。
  • 中等快速/增加聚类每年多重用药进展斜率最陡(斜率=6.4),基线及累积癌症发病率最高,生存结局最差。
  • 在Aurum和IPCI中验证良好。

关键数值与推荐

  • 多重用药定义为处方成分累计数量。
  • 高下降聚类基线多重用药截距=23.4。
  • 中等快速/增加聚类每年进展斜率=6.4。

临床怎么用

  • 在老年医学科中可参考多重用药轨迹聚类识别高死亡风险人群。
  • 对基线多重用药水平高或随时间快速增长的患者应加强评估与干预。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Polypharmacy is the use of multiple drugs. Many definitions have been established for polypharmacy, often cross-sectionally, despite it naturally changing over time. In this study, we aimed to identify clusters of older people with distinct polypharmacy trajectories over time and associated mortality risks. We then characterised the identified clusters and assessed their generalisability in two external databases. METHODS: Data were extracted from three primary care databases: the UK Clinical Practice Research Datalink (CPRD) GOLD, CPRD Aurum and the Dutch Integrated Primary Care Information (IPCI). People aged ≥65 on 1 January 2015 were included. Polypharmacy, defined as the cumulative number of prescribed ingredients, was calculated at baseline and at the end of each subsequent follow-up year (2015-19). We applied joint latent class modelling, which divides the population into clusters with different trajectories and associated mortality risks. The model was trained in GOLD and validated in Aurum and IPCI. RESULTS: Four clusters were identified and characterised based on polypharmacy baseline and rate of progression: low-steady, intermediate-slow/increasing, intermediate-fast/increasing and high-decreasing. The high-decreasing cluster had the highest average baseline polypharmacy (intercept = 23.4) and prevalence of non-cancer chronic comorbidities, whilst the intermediate-fast/increasing had the steepest polypharmacy rate of progression per year (slope = 6.4), highest baseline and cumulative incidence of cancer, and worst survival outcome. Good validation was found in Aurum and IPCI. CONCLUSION: High baseline levels and increasing levels of polypharmacy were associated with an increased mortality risk in older people. The clusters identified in this study were externally validated in two European databases, confirming their robustness and generalisability.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Elhussein L, Williams RD, Man WY, et al. Longitudinal trajectories of polypharmacy in older people, and their association with the risk of mortality: a joint latent class model analysis of real-world data from the UK and the Netherlands. Age Ageing. 2025. PMID: 40833208. doi:10.1093/ageing/afaf233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。